Company type
Keywords
Index
Reset

CIMYM BioSciences Ltd

CIMYM BioSciences was established to develop oncology and immunological therapeutics.  At CIMYM we believe passionately that drug development can only be successful if it is patient centred; ‘Begin with the patient in mind…’ As a healthcare company we recognise an exceptional idea to fill a medical need, build a network and then establish a clinical utility that will improve patient care.  CIMYM uses its expertise to manage value-enhancing activities in the development process of pharmaceuticals and diagnostics. It takes a patient-centred approach to co-develop innovative products and in turn licenses the rights for manufacture and marketing to other pharmaceutical companies for license fees and royalty payments.
Company type
R&D
Keywords
Ms Yvonne Joseph
Managing Director 
Mr Andrew Mackie
Corporate Development 

Medherant

Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018. Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use. The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system. As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.
Company type
R&D
Keywords
Mr Nigel Davis
CEO 

MediSieve

MediSieve is a London-based medical device therapeutics company developing “magnetic blood filtration”, a revolutionary method of treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. Practically any component can be specifically removed (cytokines, toxins, cells etc.), providing a platform technology that could be used to treat a huge range of blood-borne medical conditions, accessing several billion-dollar global markets. Our initial targets are sepsis, cytokine storms, leukaemia and malaria.

Website:
https://www.medisieve.com
Company type
R&D
Keywords
Dr George Frodsham
CEO 

Mereo BioPharma Group plc

Mereo BioPharma is an innovative leader in the biopharma sector with a focus on developing and optimizing the value of novel medicines acquired from large pharmaceutical companies designed to address significant unmet medical needs in rare and specialty disease areas. Mereo has built an initial mid-late stage portfolio of four exceptionally well characterised novel products, three from Novartis and one from AstraZeneca, for the treatment of diseases with considerable unmet medical need.
Website:
www.mereobiopharma.com/
Company type
R&D
Keywords
Dr Donald Coppen
Director, Corporate Development 
Mr John Richard
Head of Corporate Development 

Mironid

Company type
R&D
Dr Neil Wilkie
COO 

OxStem Limited

Company type
R&D
Dr Carolyn Porter
Chief Business Officer 
Dr Stuart Collinson
CEO 

PhoreMost Ltd

PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savings onto patients.

Company type
R&D
Keywords
Dr Sam Barker
BD & Alliances 
Dr Neil Torbett
CBO 

Shield Therapeutics

Company type
R&D
Keywords
Mr David Childs
Director of Product Supply and Commerical Alliances 
Dr Mark Sampson
Chief Medical Officer 

Therakind

Therakind is a private European pharmaceutical company with the primary objective of increasing the availability of authorised speciality medicines and ensuring that these medicines are both safe and effective.

Therakind creates, develops, and improves paediatric and other speciality medicinal products and has already successfully brought two paediatric medicines and a further speciality medicine to market. An extensive pipeline of products is under development.

Company type
R&D
Dr Susan Conroy
CEO